Saama, a provider of AI-based solutions to accelerate clinical development and commercialisation, announced on Monday an expanded, multi-year agreement with biopharmaceutical company Pfizer Inc (NYSE:PFE) aimed at accelerating clinical research processes.

Originating from their 2020 collaboration, the expanded partnership builds upon the success of Smart Data Quality (SDQ), an AI-driven solution that notably reduced Pfizer's data review timelines.

Under the new agreement, Pfizer will further implement SDQ to enhance data review processes across its global study portfolio.

Beyond SDQ, the partnership also includes the adoption of Saama's advanced Biometrics Research and Analysis Information Network. This innovative platform is poised to streamline statistical programming and biostatistics workflows, digitise study specifications and produce submission-ready tables, listings and figures (TLF) artifacts. By leveraging these AI-driven solutions, Pfizer anticipates a reduction in regulatory submission timelines, thereby accelerating the approval process for its diverse portfolio of global studies while fostering ongoing automation and innovation.